Press Releases Jan 23, 2017 • 7:05 AM EST Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference Jan 19, 2017 • 7:05 AM EST Matinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants Jan 6, 2017 • 7:35 AM EST Matinas BioPharma to Present at Biotech Showcase™ 2017 Dec 8, 2016 • 7:05 AM EST Matinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF Dec 5, 2016 • 7:05 AM EST Matinas BioPharma Commences Dosing in Phase 1 Study of Orally Administered Aminoglycoside Antibiotic MAT2501 Nov 21, 2016 • 7:05 AM EST Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis Nov 15, 2016 • 7:05 AM EST Matinas BioPharma Reports 2016 Third Quarter Financial Results and Provides Corporate Update Nov 3, 2016 • 7:35 AM EDT Matinas BioPharma Researchers Among Rutgers University Recipients of 2016 Edison Patent Awards Oct 26, 2016 • 7:35 AM EDT Matinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016 Oct 24, 2016 • 7:05 AM EDT Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology << Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ...13 | Next >>
